- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01711268
Sunitinib Drug Levels and Outcomes in Kidney Cancer (CRESTO)
Correlating Renal Cell Cancer Treatment Efficacy With Sunitinib Therapeutic Levels and Outcomes
Sunitinib is an oral drug used for treatment of advanced kidney cancer. The standard dose is 50mg, but many patients require a dose decrease due to side-effects. Drug levels of sunitinib vary approximately 10-fold between patients.
This study will measure blood levels of sunitinib and its metabolite, and correlate these with side-effects and the response to the treatment. The study aims to establish whether blood levels change with time, and see how useful blood levels are for monitoring patients treated with sunitinib.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
Rationale: Sunitinib is an oral multi-targeted tyrosine kinase inhibitor used for first-line systemic therapy in metastatic renal cell carcinoma. It is metabolised to a pharmacologically active metabolite, SU012662, which is of equal potency to the parent compound. At a standard 50mg daily dose, variability in plasma levels between patients is approximately ten-fold. In clinical trials, over 30% of patients require a dose reduction due to toxicity. However, some patients can tolerate up to 100mg without excessive toxicity. It is unknown if sunitinib clearance changes with time. Pre-clinical experiments observed tyrosine kinase inhibition at a plasma concentration of 50-100ng/ml.
Design: This is a prospective non-randomized, Phase II clinical study. Decision to treat patients with single-agent sunitinib is pre-determined by treating specialists before entering this study. Toxicity and trough sunitinib/metabolite levels will be measured every six weeks during treatment.
Aim: This study will prospectively examine the relationship between steady-state trough levels of sunitinib/metabolites and the time on treatment, in addition to changes in trough levels over time. Trough levels will also be correlated with other measures of efficacy and treatment-related toxicity. Furthermore, we aim to confirm that the putative target of 50ng/ml correlates with toxicity and time on sunitinib.
Studietype
Registrering (Forventet)
Kontakter og plasseringer
Studiekontakt
- Navn: Howard Gurney, MBBS, FRACP
- Telefonnummer: +61298455200
- E-post: howard.gurney@sydney.edu.au
Studiesteder
-
-
New South Wales
-
Westmead, New South Wales, Australia, 2145
- Rekruttering
- Crown Princess Mary Cancer Centre, Westmead Hospital
-
Ta kontakt med:
- Howard Gurney, MBBS (Hon), FRACP
- Telefonnummer: +61298455200
- E-post: howard.gurney@sydney.edu.au
-
Hovedetterforsker:
- Howard Gurney, MBBS (Hon), FRACP
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Metastatic renal cell cancer treated with single agent sunitinib
- No known primary liver disease and no other severe or uncontrolled concurrent medical conditions
- Signed informed consent
Exclusion Criteria:
- Patients who are unable to sign informed consent
- Patients unable to give blood
- Patients who are pregnant, nursing or not using an effective contraception method
- Patients who had bone-marrow-transplantation prior to sunitinib treatment
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Time to treatment failure (time on sunitinib treatment)
Tidsramme: Sunitinib duration (median)
|
This duration extends from the date the patient starts sunitinib until the date sunitinib is abandoned.
The group with sunitinib concentration below the population median are expected to have a median Time to Treatment Failure (TTF) of approximately 8 months, compared with 14 months in those with sunitinib concentration above the population median.
|
Sunitinib duration (median)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Toxicity
Tidsramme: Every 6 weeks
|
Pre-specified toxicities (BP, fatigue, diarrhoea, stomatitis, hand-foot syndrome) will be graded every 6 weeks
|
Every 6 weeks
|
Overall survival
Tidsramme: 2 years
|
Measured from the date of starting sunitinib treatment to the date of death from any cause
|
2 years
|
Progression-free survival
Tidsramme: 2 years
|
Progression as determined by the clinician according to RECIST 1.1 definitions
|
2 years
|
Time to second line therapy
Tidsramme: 2 years
|
Date of starting sunitinib treatment to the date further systemic therapy is started
|
2 years
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Howard Gurney, MBBS, FRACP, Crown Princess Mary Cancer Centre, Westmead
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- HGWH008
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Nyrecellekarsinom
-
Debiopharm International SARekrutteringPankreas duktal adenokarsinom (PDAC) | Kolorektal kreft (CRC) | Clear Cell Renal Cell Cancer (ccRCC)Frankrike, Australia
-
University of Michigan Rogel Cancer CenterFullførtNyrecellekarsinomForente stater
-
Universitaire Ziekenhuizen KU LeuvenFullførtForekomst av utvidet renal clearance | Risikofaktorer for økt renal clearanceBelgia
-
Second Affiliated Hospital of Guangzhou Medical...Hunan Zhaotai Yongren Medical Innovation Co. Ltd.RekrutteringAnti-kreft celle immunterapi | T Cell og NK CellKina
-
Andrew B AdamsBristol-Myers SquibbFullført
-
University Health Network, TorontoFullførtGlomerulær filtreringshastighet | Renal blodstrømCanada
-
Peking University People's HospitalUkjentNatural Killer Cell Medited ImmunitetKina
-
Center for International Blood and Marrow Transplant...Cellular Dynamics International, Inc. - A FUJIFILM CompanyAvsluttetiPS Cell Manufacturing and Banking
-
Oregon Health and Science UniversityFullført
-
Erling Bjerregaard PedersenUniversity of AarhusUkjentRenal rørtransportDanmark